You are here:
Calquence
Acalabrutinib monotherapy for second line or later treatment of relapsed or refractory mantle cell lymphoma in adults and elderly
No estimate possible yet
15,491,346.00
Registration application pending
Acalabrutinib
Hematology
Indication extension
Aggressive non-Hodgkin’s lymphoma
AstraZeneca
Tyrosine kinase inhibitor
Oral
Tablet
Intermural (MSZ)
Centralised (EMA)
Normal trajectory
No
September 2024
July 2025
Yes
Verwachte registratie op basis van EMA-indiening in september 2024 en een gemiddelde doorlooptijd van 10 maanden voor een indicatieuitbreiding.
Rituximab-CHOP of BR
continuous
2 times a day
100 mg
NCT02213926 (ACE-LY-004) (1); Wang et al. Lancet. 2017 (2).
< 247
Market share is generally not included unless otherwise stated.
NKR 2022 (1)
In 2022 waren er 247 patiënten gediagnosticeerd met mantelcellymfoom (1).
< 62,718.00
Z-Index 2022; ZIN pakketadvies acalabrutinib 2022
De apotheekinkoopprijs van acalabrutinib is €4.811,27 voor 56 tabletten met 100mg acalabrutinib (Z-Index). De aanbevolen dagelijkse dosering is 200mg (2 capsules) waarmee de kosten op €171,83 per dag komen. De kosten voor behandeling met acalabrutinib komen daarmee op €62.718 per jaar.
This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.
There is currently nothing known about off label use.
There is currently nothing known about indication extensions.
There is currently no futher information available.
Understanding of expected market entry of innovative medicines